NASDAQ:COCP Cocrystal Pharma Q4 2025 Earnings Report $1.06 -0.07 (-5.80%) As of 01:05 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cocrystal Pharma EPS ResultsActual EPS-$0.17Consensus EPS -$0.18Beat/MissBeat by +$0.01One Year Ago EPSN/ACocrystal Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACocrystal Pharma Announcement DetailsQuarterQ4 2025Date3/31/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsCocrystal Pharma's next earnings date is estimated for Thursday, August 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Cocrystal Pharma Earnings HeadlinesCOCP: Presentation highlights CDI-988June 1 at 10:52 PM | msn.comCocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and InfluenzaMay 26, 2026 | globenewswire.comStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.June 2 at 1:00 AM | Porter & Company (Ad)Cocrystal Pharma IncMay 17, 2026 | edition.cnn.comCocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 15, 2026 | globenewswire.comCocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus InfectionApril 30, 2026 | globenewswire.comSee More Cocrystal Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cocrystal Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cocrystal Pharma and other key companies, straight to your email. Email Address About Cocrystal PharmaCocrystal Pharma (NASDAQ:COCP) (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development. The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections. Lead projects target influenza A and B polymerases as well as key enzymes in coronaviruses such as SARS-CoV-2. Additional research efforts are directed at antiviral targets in hepatitis B virus, norovirus and other emerging viral threats, reflecting Cocrystal’s commitment to addressing a broad spectrum of infectious diseases. Founded in 2006 and headquartered in Bothell, Washington, Cocrystal Pharma leverages collaborations with academic institutions and contract research organizations to expand its drug discovery capabilities. The company maintains research laboratories in the Seattle area and operates a business development office in New York City to engage with strategic partners and investors globally. Under the leadership of founder and Chief Executive Officer Kenneth T. Hitchcock, Ph.D., Cocrystal Pharma seeks to address unmet medical needs in antiviral therapy. By combining deep structural biology expertise with a scalable discovery engine, the company aims to advance novel antivirals poised to combat both seasonal outbreaks and future pandemic threats.View Cocrystal Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Reasons to Pony Up for Pony AI Stock—and 1 Reason to WaitBraze Blazes Ahead on Q1 2027 Earnings Beat, Raised GuidanceDrone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked NameMarketBeat Week in Review – 05/25 - 05/29Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemMongoDB's AI Advantage Is Starting to Show Up in Results Upcoming Earnings Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
